{"title":"抑制溶酶体醛缩酶:AMPK激活治疗代谢性疾病的灵丹妙药?","authors":"D. Carling","doi":"10.1093/lifemeta/loac027","DOIUrl":null,"url":null,"abstract":"\n In a tour-de-force study by Zhang and colleagues recently published in Nature Metabolism, a newly identified aldolase inhibitor, Aldometanib, is shown to activate lysosomal AMPK. Remarkably, mice treated with Aldometanib have increased insulin sensitivity, lowered blood glucose, decreased hepatic steatosis and fibrosis and are long-lived, effects of which all appear to be mediated via activation of lysosomal AMPK.","PeriodicalId":74074,"journal":{"name":"Life metabolism","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Inhibiting lysosomal aldolase: a magic bullet for AMPK activation in treating metabolic disease?\",\"authors\":\"D. Carling\",\"doi\":\"10.1093/lifemeta/loac027\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n In a tour-de-force study by Zhang and colleagues recently published in Nature Metabolism, a newly identified aldolase inhibitor, Aldometanib, is shown to activate lysosomal AMPK. Remarkably, mice treated with Aldometanib have increased insulin sensitivity, lowered blood glucose, decreased hepatic steatosis and fibrosis and are long-lived, effects of which all appear to be mediated via activation of lysosomal AMPK.\",\"PeriodicalId\":74074,\"journal\":{\"name\":\"Life metabolism\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-10-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Life metabolism\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/lifemeta/loac027\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Life metabolism","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/lifemeta/loac027","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Inhibiting lysosomal aldolase: a magic bullet for AMPK activation in treating metabolic disease?
In a tour-de-force study by Zhang and colleagues recently published in Nature Metabolism, a newly identified aldolase inhibitor, Aldometanib, is shown to activate lysosomal AMPK. Remarkably, mice treated with Aldometanib have increased insulin sensitivity, lowered blood glucose, decreased hepatic steatosis and fibrosis and are long-lived, effects of which all appear to be mediated via activation of lysosomal AMPK.